<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32410106</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>30</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1573-6830</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>41</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cellular and molecular neurobiology</Title>
          <ISOAbbreviation>Cell Mol Neurobiol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Time-Dependent Memory and Gait Improvement by Intranasally-Administered Extracellular Vesicles in Parkinson's Disease Model Rats.</ArticleTitle>
        <Pagination>
          <StartPage>605</StartPage>
          <EndPage>613</EndPage>
          <MedlinePgn>605-613</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10571-020-00865-8</ELocationID>
        <Abstract>
          <AbstractText>We have recently demonstrated that extracellular vesicles (EVs) derived from the human teeth stem cells improve motor symptoms and normalize tyrosine hydroxylase (TH) expression in the nigrostriatal structures of Parkinson's disease (PD) model rats obtained by 6-hydroxydopamine (6-OHDA) unilateral injection into the medial forebrain bundle (MFB). The aim of this study was to clarify: (1) how long therapeutic effects persist after discontinuation of 17-day intranasal administration of EVs in 6-OHDA rats; (2) may EVs reverse cognitive (learning/memory) dysfunction in these PD model rats; (3) whether and how the behavioral improvement may be related to the expression of TH and Nissl bodies count in the nigrostriatal structures. Our results demonstrated that in 6-OHDA rats, gait was normalized even ten days after discontinuation of EVs administration. EVs successfully reversed 6-OHDA-induced impairment in spatial learning/memory performance; however, the beneficial effect was shorter (up to post-treatment day 6) than that revealed for gait improvement. The shorter effect of EVs coincided with both full normalization of TH expression and Nissl bodies count in the nigrostriatal structures, while slight but significant increase in the 6-OHDA-decreased Nissl count persisted in the substantia nigra even on the post-treatment day 20, supposedly due to the continuation of protein synthesis in the living cells. The obtained data indicate the usefulness of further studies to find the optimal administration regimen which could be translated into clinical trials on PD patients, as well as to clarify other-apart from dopaminergic-neuromodulatory pathways involved in the EVs mechanism of action.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Narbute</LastName>
            <ForeName>Karīna</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0002-5358-6194</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Faculty of Medicine, University of Latvia, 3 Jelgavas St, Riga, 1004, Latvia. karina.narbute@lu.lv.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pilipenko</LastName>
            <ForeName>Vladimirs</ForeName>
            <Initials>V</Initials>
            <Identifier Source="ORCID">0000-0002-7098-7483</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Faculty of Medicine, University of Latvia, 3 Jelgavas St, Riga, 1004, Latvia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pupure</LastName>
            <ForeName>Jolanta</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0001-8356-5071</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Faculty of Medicine, University of Latvia, 3 Jelgavas St, Riga, 1004, Latvia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Klinovičs</LastName>
            <ForeName>Toms</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0002-1413-1074</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Faculty of Medicine, University of Latvia, 3 Jelgavas St, Riga, 1004, Latvia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Auders</LastName>
            <ForeName>Jānis</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0003-0890-4541</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Faculty of Medicine, University of Latvia, 3 Jelgavas St, Riga, 1004, Latvia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jonavičė</LastName>
            <ForeName>Ugnė</ForeName>
            <Initials>U</Initials>
            <Identifier Source="ORCID">0000-0002-4882-7918</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Stem Cell Biology, State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kriaučiūnaitė</LastName>
            <ForeName>Karolina</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0003-2879-7595</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Stem Cell Biology, State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pivoriūnas</LastName>
            <ForeName>Augustas</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0001-7009-2535</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Stem Cell Biology, State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kluša</LastName>
            <ForeName>Vija</ForeName>
            <Initials>V</Initials>
            <Identifier Source="ORCID">0000-0003-3263-8001</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Faculty of Medicine, University of Latvia, 3 Jelgavas St, Riga, 1004, Latvia.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>05</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cell Mol Neurobiol</MedlineTA>
        <NlmUniqueID>8200709</NlmUniqueID>
        <ISSNLinking>0272-4340</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>8HW4YBZ748</RegistryNumber>
          <NameOfSubstance UI="D016627">Oxidopamine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.16.2</RegistryNumber>
          <NameOfSubstance UI="D014446">Tyrosine 3-Monooxygenase</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000281" MajorTopicYN="N">Administration, Intranasal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000067128" MajorTopicYN="N">Extracellular Vesicles</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005684" MajorTopicYN="Y">Gait</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008568" MajorTopicYN="Y">Memory</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009562" MajorTopicYN="N">Nissl Bodies</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016627" MajorTopicYN="N">Oxidopamine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014446" MajorTopicYN="N">Tyrosine 3-Monooxygenase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Extracellular vesicles</Keyword>
        <Keyword MajorTopicYN="N">Gait</Keyword>
        <Keyword MajorTopicYN="N">Learning/memory</Keyword>
        <Keyword MajorTopicYN="N">Parkinson’s disease model</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32410106</ArticleId>
        <ArticleId IdType="doi">10.1007/s10571-020-00865-8</ArticleId>
        <ArticleId IdType="pii">10.1007/s10571-020-00865-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Alvarez-Erviti L, Seow Y, Yin H et al (2011) Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 29:341–345. https://doi.org/10.1038/nbt.1807</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nbt.1807</ArticleId>
            <ArticleId IdType="pubmed">21423189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boix J, von Hieber D, Connor B (2018) Gait analysis for early detection of motor symptoms in the 6-ohda rat model of parkinson’s disease. Front Behav Neurosci 12:1–15. https://doi.org/10.3389/fnbeh.2018.00039</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnbeh.2018.00039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cosgrove J, Alty JE, Jamieson S (2015) Cognitive impairment in Parkinson’s disease. Postgrad Med J 91:212–220. https://doi.org/10.1136/postgradmedj-2015-133247</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/postgradmedj-2015-133247</ArticleId>
            <ArticleId IdType="pubmed">25814509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Leonibus E, Pascucci T, Lopez S et al (2007) Spatial deficits in a mouse model of Parkinson disease. Psychopharmacology 194:517–525. https://doi.org/10.1007/s00213-007-0862-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00213-007-0862-4</ArticleId>
            <ArticleId IdType="pubmed">17619858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferro MM, Bellissimo MI, Anselmo-Franci JA et al (2005) Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson’s disease: histological, neurochemical, motor and memory alterations. J Neurosci Methods 148:78–87. https://doi.org/10.1016/j.jneumeth.2005.04.005</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneumeth.2005.04.005</ArticleId>
            <ArticleId IdType="pubmed">15939479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabriel AF, Marcus MAE, Honig WMM, Walenkamp GHIM, Joosten EAJ (2007) The catWalk method: a detailed analysis of behavioral changes after acute inflammatory pain in the rat. J Neurosci Methods 148:9–16. https://doi.org/10.1016/j.jneumeth.2007.02.003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneumeth.2007.02.003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>García-Cabezas M, John YJ, Barbas H, Zikopoulos B (2016) Distinction of neurons, glia and endothelial cells in the cerebral cortex: an algorithm based on cytological features. Front Neuroanat 10:1–28. https://doi.org/10.3389/fnana.2016.00107</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnana.2016.00107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gyorgy B, Hung ME, Breakefield XO, Leonard JN (2015) Therapeutic applications of extracellular vesicles: clinical promise and open questions. Annu Rev Pharmacol Toxicol 55:439–464. https://doi.org/10.1146/annurev-pharmtox-010814-124630</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-pharmtox-010814-124630</ArticleId>
            <ArticleId IdType="pubmed">25292428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hely MA, Reid WGJ, Adena MA et al (2008) The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 23:837–844. https://doi.org/10.1002/mds.21956</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mds.21956</ArticleId>
            <ArticleId IdType="pubmed">18307261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarmalaviciute A, Tunaitis V, Pivoraite U et al (2015) Exosomes from dental pulp stem cells rescue human dopaminergic neurons from 6-hydroxy-dopamine-induced apoptosis. Cytotherapy 17:932–939. https://doi.org/10.1016/j.jcyt.2014.07.013</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jcyt.2014.07.013</ArticleId>
            <ArticleId IdType="pubmed">25981557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kourembanas S (2015) Exosomes: vehicles of intercellular signaling, biomarkers, and vectors of cell therapy. Annu Rev Physiol 77:13–27. https://doi.org/10.1146/annurev-physiol-021014-071641</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-physiol-021014-071641</ArticleId>
            <ArticleId IdType="pubmed">25293529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lindner MD, Cain CK, Plone MA et al (1999) Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats. Behav Brain Res 102:1–16. https://doi.org/10.1016/S0166-4328(98)00160-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0166-4328(98)00160-0</ArticleId>
            <ArticleId IdType="pubmed">10403011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maas SLN, Breakefield XO, Weaver AM (2017) Extracellular vesicles: unique intercellular delivery vehicles. Trends Cell Biol 27:172–188. https://doi.org/10.1016/j.tcb.2016.11.003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tcb.2016.11.003</ArticleId>
            <ArticleId IdType="pubmed">27979573</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Metz GA, Tse A, Ballermann M, Smith LK, Fouad K (2005) The unilateral 6-OHDA rat model of Parkinson’s disease revisited: an electromyographic and behavioural analysis. Eur J Neurosci 22:735–744. https://doi.org/10.1111/j.1460-9568.2005.04238.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1460-9568.2005.04238.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murphy DE, de Jong OG, Brouwer M et al (2019) Extracellular vesicle-based therapeutics: natural versus engineered targeting and trafficking. Exp Mol Med. https://doi.org/10.1038/s12276-019-0223-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s12276-019-0223-5</ArticleId>
            <ArticleId IdType="pubmed">30872574</ArticleId>
            <ArticleId IdType="pmc">6418170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Narbute K, Piļipenko V, Pupure J et al (2019) Intranasal administration of extracellular vesicles derived from human teeth stem cells improves motor symptoms and normalizes tyrosine hydroxylase expression in the substantia nigra and striatum of the 6-hydroxydopamine-treated rats. Stem Cells Transl Med 8:490–499. https://doi.org/10.1002/sctm.18-0162</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/sctm.18-0162</ArticleId>
            <ArticleId IdType="pubmed">30706999</ArticleId>
            <ArticleId IdType="pmc">6477008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Gorman Tuura RL, Baumann CR, Baumann-Vogel H (2018) Beyond dopamine: GABA, glutamate, and the axial symptoms of Parkinson disease. Front Neurol 9:806. https://doi.org/10.3389/fneur.2018.00806</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2018.00806</ArticleId>
            <ArticleId IdType="pubmed">30319535</ArticleId>
            <ArticleId IdType="pmc">6168661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perets N, Betzer O, Shapira R et al (2019) Golden Exosomes selectively target brain pathologies in neurodegenerative and neurodevelopmental disorders. Nano Lett 19:3422–3431. https://doi.org/10.1021/acs.nanolett.8b04148</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.nanolett.8b04148</ArticleId>
            <ArticleId IdType="pubmed">30761901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pilipenko V, Narbute K, Pupure J et al (2019) Neuroprotective action of diazepam at very low and moderate doses in Alzheimer’s disease model rats. Neuropharmacology 144:319–326. https://doi.org/10.1016/j.neuropharm.2018.11.003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuropharm.2018.11.003</ArticleId>
            <ArticleId IdType="pubmed">30408486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thery C, Amigorena S, Raposo G, Clayton A (2006) Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc cell Biol. https://doi.org/10.1002/0471143030.cb0322s30</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/0471143030.cb0322s30</ArticleId>
            <ArticleId IdType="pubmed">18228490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tolosa E, Compta Y, Gaig C (2007) The premotor phase of Parkinson’s disease. Parkinsonism Relat Disord 13(Suppl):S2–7. https://doi.org/10.1016/j.parkreldis.2007.06.007</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.parkreldis.2007.06.007</ArticleId>
            <ArticleId IdType="pubmed">17681839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang T, Martin P, Fogarty B et al (2015) Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio. Pharm Res 32:2003–2014. https://doi.org/10.1007/s11095-014-1593-y</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11095-014-1593-y</ArticleId>
            <ArticleId IdType="pubmed">25609010</ArticleId>
            <ArticleId IdType="pmc">4520542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng J, Tan J, Miao Y-Y, Zhang Q (2019) Extracellular vesicles degradation pathway based autophagy lysosome pathway. Am J Transl Res 11:1170–1183</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30972154</ArticleId>
            <ArticleId IdType="pmc">6456539</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
